Characteristics of 5-year survivors
| Pt | Primary histology | Dx - CPI (months) | M stage | First CPI | PFS (months) | Subsequent systemic Rx | Local | Regional | OS (months) | Vital status |
| 1 | Acral | 34 | M1a | CTLA-4 | 4 | PD-1, chemo, trial | None | ILP | 90 | DOD |
| 2 | Acral | 14 | M1a | CTLA-4 | 8 | PD-1, sorafenib | SRS, surg, SBRT | RT | 79 + | NED |
| 3 | Mucosal | 4 | M1c | CTLA-4+PD-1 | 38 CR | CTLA-4+PD-1 | None | None | 99+ | NED |
| 4 | Mucosal | 37 | M1c | CTLA-4+PD-1 | 18 | None | Surg, SBRT | RT | 71+ | NED |
| 5 | Mucosal | 13 | M1b | CTLA-4+PD-1 | 6 | None | SRS, surg | None | 79+ | NED |
| 6 | Mucosal | 37 | M1a | CTLA-4+PD-1 | 35 | ACT, BRAF-i | Surg | None | 82 | DOD |
| 7 | Uveal | 22 | M1c | CTLA-4 | 80 CR+ | PD-1* | None | None | 80+ | NED |
| 8 | Uveal | 167 | M1c | CTLA-4 | 6 | PD-1 | SRS, surg | RT | 62+ | NED |
| 9 | Uveal | 44 | M1c | CTLA-4 | 15 | PD-1 | SRS | ChEmb, RT | 67 | DOD |
| 10 | Uveal | 199 | M1c | CTLA-4 | 42 CR | PD-1, trial | None | None | 90+ | AWD |
Ten patients with 5-year survival are shown. Dx-CPI indicates the time interval between initial diagnosis and first treatment with CPI. ‘+’ indicates ongoing CR or survival.
*Denotes a patient with stable disease who was started on anti-PD-1 before progression occurred.
AWD, alive with disease; ChEmb, hepatic chemoembolization; CPI, checkpoint inhibitor; CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; DOD, died of disease; Dx, Diagnosis; ILP, isolated limb perfusion; NED, no evidence of disease; OS, overall survival; PD-1, programmed death 1 receptor; PFS, progression-free survival; RT, wide-field radiation therapy; Rx, treatment; SBRT, stereotactic body radiotherapy to extracranial metastases; SRS, stereotactic radiosurgery for central nervous system metastases; Surg, surgery.